Literature DB >> 7773501

Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.

W Gorczyca1, M Markiewski, A Kram, T Tuziak, W Domagala.   

Abstract

We examined 59 breast cancers for p53 and bcl-2 protein expression by immunohistochemistry. The results were correlated with Ki-67 immunostaining. p53-negativity was noted in 40 cases and the remaining 19 tumours were p53-positive. Thirty-six tumours showed strong expression of bcl-2 and in 23 no staining for this protein was observed. We found statistically significant reverse correlation between expression of p53 and bcl-2 in majority of carcinomas: 31 cases were bcl-2 positive and p53-negative, and 14 tumours were bcl-2-negative and p53-positive. Six carcinomas showed no nuclear staining for Ki-67 and in the remaining 53 the percent of cancer cells positive for Ki-67 ranged from 1 to 60 (mean: 14.6). In these 53 cases we found that bcl-2-positive tumours were characterized by lower proliferation than bcl-2-negative tumours, the mean value of Ki-67 immunostaining being 10.7% and 23.0%, respectively. p53-negative tumours showed lower proliferation than p53-positive tumours: mean Ki-67 index was 10.2% and 23.9%, respectively. We conclude that immunohistochemically detected p53 and bcl-2 proteins show a significant inverse relationship in majority of breast carcinomas and their expression correlates with tumour proliferation (Ki-67 immunostaining).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773501     DOI: 10.1007/bf00191359

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

Review 1.  The apoptosis endonuclease and its regulation.

Authors:  A H Wyllie; M J Arends; R G Morris; S W Walker; G Evan
Journal:  Semin Immunol       Date:  1992-12       Impact factor: 11.130

Review 2.  Bcl-2 initiates a new category of oncogenes: regulators of cell death.

Authors:  S J Korsmeyer
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

Review 3.  Cell death by apoptosis and its protective role against disease.

Authors:  W Bursch; F Oberhammer; R Schulte-Hermann
Journal:  Trends Pharmacol Sci       Date:  1992-06       Impact factor: 14.819

4.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

Authors:  D M Hockenbery; M Zutter; W Hickey; M Nahm; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

5.  p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study.

Authors:  J L Ostrowski; A Sawan; L Henry; C Wright; J A Henry; C Hennessy; T J Lennard; B Angus; C H Horne
Journal:  J Pathol       Date:  1991-05       Impact factor: 7.996

6.  Expression of ras Rb1 and p53 proteins in human breast cancer.

Authors:  D A Spandidos; H Karaiossifidi; A Malliri; S Linardopoulos; S Vassilaros; A Tsikkinis; J K Field
Journal:  Anticancer Res       Date:  1992 Jan-Feb       Impact factor: 2.480

7.  Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma.

Authors:  F Pezzella; H Morrison; M Jones; K C Gatter; D Lane; A L Harris; D Y Mason
Journal:  Histopathology       Date:  1993-01       Impact factor: 5.087

8.  Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.

Authors:  W Domagala; B Harezga; A Szadowska; M Markiewski; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

9.  Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation.

Authors:  M Trudel; L Mulligan; W Cavenee; R Margolese; J Côté; G Gariépy
Journal:  Hum Pathol       Date:  1992-12       Impact factor: 3.466

10.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

View more
  7 in total

1.  Bcl-2 expression and allelic loss of the p53 gene in gastric carcinomas.

Authors:  M Saegusa; Y Takano; Y Kamata; J Okayasu
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells.

Authors:  Mei-Juan Wang; Dong-Sheng Pei; Guo-Wei Qian; Xiao-Xing Yin; Qian Cheng; Lian-Tao Li; Hui-Zhong Li; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2011-05-25

3.  An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplasia and pancreatic cancer.

Authors:  R Tomaszewska; D Karcz; J Stachura
Journal:  Int J Pancreatol       Date:  1999-12

4.  Impact of biomarkers expression before and after portal vein embolization on recurrence after two-stage hepatectomy for colorectal liver metastases.

Authors:  Masato Narita; Elie Oussoultzoglou; Marie-Pierre Chenard; Pascal Fuchshuber; Edoardo Rosso; Patrick Pessaux; Daniel Jaeck; Philippe Bachellier
Journal:  J Gastrointest Surg       Date:  2011-11-29       Impact factor: 3.452

5.  Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

Authors:  W Y Chan; K K Cheung; J O Schorge; L W Huang; W R Welch; D A Bell; R S Berkowitz; S C Mok
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

6.  Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia.

Authors:  A Dursun; A Poyraz; C Sezer; G Akyol
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

7.  Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.

Authors:  P Dettmar; N Harbeck; C Thomssen; L Pache; P Ziffer; K Fizi; F Jänicke; W Nathrath; M Schmitt; H Graeff; H Höfler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.